Scarica l'app Stockscreener
27.14
2.06%
-0.58
Dopo l'orario di chiusura:
26.88
-0.26
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$27.72
Aprire:
$27.78
Volume 24 ore:
1.33M
Relative Volume:
0.63
Capitalizzazione di mercato:
$2.75B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-14.99
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
-2.97%
1M Prestazione:
+16.17%
6M Prestazione:
+36.57%
1 anno Prestazione:
+9.92%
Intervallo 1D:
$26.25
$27.95
Intervallo di 1 settimana:
$26.25
$28.70
Portata 52W:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.14 | 2.81B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance
(BEAM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
12 Best Genomics Stocks to Invest In - Insider Monkey
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
Will Beam Therapeutics Inc. stock benefit from infrastructure spendingCurrency Fluctuation Impact & Free High Impact Stock Picks - Bollywood Helpline
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy - Finviz
Prime Editing & CRISPR Market Set to Revolutionize Gene Therapy: - openPR.com
Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Is Beam Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & Daily Price Action Insights - Улправда
Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - Улправда
Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Will Beam Therapeutics Inc. stock reach all time highs in 20252025 Buyback Activity & Low Risk High Win Rate Picks - DonanımHaber
Will Beam Therapeutics Inc. stock beat EPS estimatesCEO Change & Capital Protection Trading Alerts - DonanımHaber
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Market WrapUp & Long Hold Capital Preservation Tips - Улправда
Beam Therapeutics Inc. $BEAM Shares Acquired by Squarepoint Ops LLC - MarketBeat
Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 EndofMonth & Reliable Price Breakout Signals - Улправда
How resilient is Beam Therapeutics Inc. stock in market downturnsJuly 2025 Price Swings & Daily Growth Stock Investment Tips - Улправда
Technical Analysis: Why Beam Therapeutics Inc stock is trending among retail tradersTrade Signal Summary & Weekly Momentum Picks - moha.gov.vn
Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Bellevue Group AG Raises Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
Beam Therapeutics Inc. $BEAM Holdings Lowered by Redmile Group LLC - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Evercore ISI Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions - PR Newswire
Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities - The Globe and Mail
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com Nigeria
Beam Therapeutics stock rises on promising sickle cell therapy data - Investing.com
(BEAM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Reveals Positive Trial Results at Hemat - GuruFocus
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON Sickle Cell Trial Results and Renewed Momentum - Yahoo Finance
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential - Yahoo Finance
Beam reports positive data from sickle cell disease gene therapy trial By Investing.com - Investing.com South Africa
Beam reports positive data from sickle cell disease gene therapy trial - Investing.com
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Reports Promising Updates on Risto-cel for Sickle Cell Disease at 67th ASH Annual Meeting - Quiver Quantitative
Beam Therapeutics (Nasdaq: BEAM) posts SCD Phase 1/2 data with HbF >60% and HbS - Stock Titan
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beam Therapeutics Inc Azioni (BEAM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):